Carastock.

Nov 28, 2023 · Market cap is calculated by taking a company's price per share and multiplying it by the company's total number of shares outstanding. $152.77M. -68.8%. Market Cap / Employee. The market cap of a ... Cara Therapeutics Inc (NASDAQ: CARA) shares dive after as investors react to topline results from its KARE Phase 2 trial evaluating oral Korsuva (difelikefalin tablets) for the treatment of ...Cara Therapeutics Inc (CARA) stock has fallen -6.06% while the S&P 500 has risen 0.34% as of 12:40 PM on Tuesday, Nov 7. CARA has fallen -$0.08 from the previous closing price of $1.33 on volume of 223,033 shares. Over the past year the S&P 500 has gained 15.08% while CARA has fallen -86.62%. CARA lost -$2.07 per share the …The current Cara Therapeutics [ CARA] share price is $1.09. The Score for CARA is 25, which is 50% below its historic median score of 50, and infers higher risk than normal. CARA is currently trading in the 20-30% percentile range relative to its historical Stock Score levels. Cara Therapeutics Stock Forecast, CARA stock price prediction. Price target in 14 days: 1.492 USD. The best long-term & short-term Cara Therapeutics share ...

What happened. Cara Therapeutics ( CARA 9.63%) was a hot stock on Tuesday. One of the formerly clinical-stage biotech's drug candidates won FDA approval, and investors reacted in the usual manner ...

Cara Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 3,420,000 shares, an increase of 15.2% from the previous total of 2,970,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment.

Find the latest analyst research for Cara Therapeutics, Inc. Common Stock (CARA) at Nasdaq.com.Nov 22, 2023 · Future criteria checks 2/6. Cara Therapeutics is forecast to grow earnings and revenue by 10.7% and 39.6% per annum respectively. EPS is expected to grow by 27.7% per annum. Return on equity is forecast to be -187% in 3 years. Post #2,000. Item 8.01 Other Information. As previously disclosed, on August 23, 2021, Cara Therapeutics, Inc. (“Cara”) received approval of its New Drug Application for KORSUVA™ injection for the treatment of moderate-to-severe pruritus in hemodialysis patients from the U.S. Food and Drug Administration (the “Approval Milestone”).A high-level overview of Cara Therapeutics, Inc. (CARA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

Find the latest Cara Therapeutics, Inc. (CARA) stock quote, history, news and other vital information to help you with your stock trading and investing.

NasdaqGM:CARA Stock Report. Mkt Cap: US$52.2m. Add to watchlist. Company Overview; 1 Valuation; 2 Future Growth; 3 Past Performance; 4 Financial Health; 5 Dividend; 6 Management; 7 Ownership; Other Information; View Management. Cara Therapeutics Ownership. Who are the major shareholders and have insiders been buying or selling?

Complete Cara Therapeutics Inc. stock information by Barron's. View real-time CARA stock price and news, along with industry-best analysis.Cara Therapeutics, Inc. (CARA) stock forecast and price target. Find the latest Cara Therapeutics, Inc. CARA analyst stock forecast, price target, and recommendation trends with in-depth analysis ...According to the issued ratings of 6 analysts in the last year, the consensus rating for Cara Therapeutics stock is Moderate Buy based on the current 1 sell rating, 1 hold rating and 4 buy ratings for CARA. The average twelve-month price prediction for Cara Therapeutics is $15.86 with a high price target of $25.00 and a low price target of $4.00.In 2022, CARA's revenue was $41.87 million, an increase of 81.81% compared to the previous year's $23.03 million. Losses were -$85.47 million, -3.35% less than ...The stock of Cara Therapeutics Inc (CARA) has seen a -11.28% decrease in the past week, with a -16.90% drop in the past month, and a -60.67% decrease in the past quarter. The volatility ratio for the week is 10.49%, and the volatility levels for the past 30 days are at 10.66% for CARA.Complete Cara Therapeutics Inc. stock information by Barron's. View real-time CARA stock price and news, along with industry-best analysis.

Mar 31, 2023 · What's Happening With CARA Stock Today? Cara Therapeutics Inc (CARA) stock is trading at $5.05 as of 2:41 PM on Friday, Mar 31, an increase of $0.16, or 3.27% from the previous closing price of $4.89. The stock has traded between $4.90 and $5.06 so far today. Cara Therapeutics Inc’s ( CARA) price is currently down 49.02% so far this month. During the month of March, Cara Therapeutics Inc’s stock price has reached a high of $10.39 and a low of $5.17. Over the last year, Cara Therapeutics Inc has hit prices as high as $13.97 and as low as $5.24. Year to date, Cara Therapeutics Inc’s stock is ...Stock Price Forecast. According to 8 stock analysts, the average 12-month stock price forecast for CARA stock stock is $15.13, which predicts an increase of ...Cara Therapeutics (CARA) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2022. This widely-known consensus ...As of March 10, 2023, 4:00 PM CST, Cara Therapeutics Inc’s stock price was $6.06. Cara Therapeutics Inc is down 5.16% from its previous closing price of $6.39. During the last market session, Cara Therapeutics Inc’s stock traded between $6.24 and $6.71. Currently, there are 53.76 million shares of Cara Therapeutics Inc stock available for ...

The average price recommended by analysts for Cara Therapeutics Inc (CARA) is $10.29, which is $9.33 above the current market price. The public float for CARA is 46.23M and currently, short sellers hold a 6.42% of that float. On November 24, 2023, CARA’s average trading volume was 599.48K shares. Top 5 EV Tech Stocks to Buy for …What's Happening with CARA Stock Today. Cara Therapeutics Inc (CARA) stock is higher by 2.07% while the S&P 500 is higher by 1.41% as of 3:38 PM on Wednesday, Mar 29. CARA is higher by $0.10 from the previous closing price of $4.94 on volume of 309,020 shares. Over the past year the S&P 500 is down -13.05% while CARA …

Overview. Founded in 2004 with headquarters in Connecticut (84 employees), Cara Therapeutics currently sports an enterprise value of ~$350M and Q2 cash position of $204M providing them operational ...Simply Wall St. May 25, 2023 at 6:40 AM · 3 min read. You may think that with a price-to-sales (or "P/S") ratio of 4.4x Cara Therapeutics, Inc. ( NASDAQ:CARA) is a stock to potentially avoid ...According to 8 stock analysts, the average 12-month stock price forecast for CARA stock stock is $15.13, which predicts an increase of 1,327.36%. The lowest target is $1.00 and the highest is $28. On average, analysts rate CARA stock stock as a strong buy.Dec 1, 2023 · According to the issued ratings of 6 analysts in the last year, the consensus rating for Cara Therapeutics stock is Moderate Buy based on the current 1 sell rating, 1 hold rating and 4 buy ratings for CARA. The average twelve-month price prediction for Cara Therapeutics is $15.86 with a high price target of $25.00 and a low price target of $4.00. Get the latest news and real-time alerts from Cara Therapeutics, Inc. (CARA) stock at Seeking Alpha.Cara Therapeutics, Inc. Common Stock. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is ... Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus.Cara Therapeutics Inc’s trailing 12-month revenue is $27.2 million with a -410.9% profit margin. Year-over-year quarterly sales growth most recently was -70.0%. Analysts expect adjusted earnings to reach $-1.998 per share for the current fiscal year. Cara Therapeutics Inc does not currently pay a dividend.Complete Cara Therapeutics Inc. stock information by Barron's. View real-time CARA stock price and news, along with industry-best analysis.

Overview. Founded in 2004 with headquarters in Connecticut (84 employees), Cara Therapeutics currently sports an enterprise value of ~$350M and Q2 cash position of $204M providing them operational ...

Cara Therapeutics' CEO is Chris Posner, appointed in Nov 2021, has a tenure of 5.25 years. total yearly compensation is $2.51M, comprised of 27.9% salary and 72.1% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth $84.15K. The average tenure of the management team and the board of …

The Trend in the Analyst Price Target. CARA's average price target has moved down $22.12 over the prior 42 months. Over the past 45 weeks, CARA's average upside potential has been 426.28%. Date.Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties ...Find the latest analyst research for Cara Therapeutics, Inc. Common Stock (CARA) at Nasdaq.com. Nov 29, 2023 · The Cara Therapeutics stock price fell by -1.90% on the last day (Wednesday, 29th Nov 2023) from $0.98 to $0.96. During the last trading day the stock fluctuated 7.37% from a day low at $0.95 to a day high of $1.02. The price has fallen in 6 of the last 10 days and is down by -12.47% for this period. Volume has increased on the last day by 227 ... Stock analysis for Cara Therapeutics Inc (CARA:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.The above table shows the PS ratio for CARA vs its peers. Here we also display the market cap and forecasted growth for additional consideration. Price-To-Sales vs Peers: CARA is good value based on its Price-To-Sales Ratio (2.8x) compared to the peer average (7.9x).PT Solutions Physical Therapy. Jun 2022 - Present1 year 4 months. • Develop practice-wide HR policies and procedures, including licensure and certification policy, and code of conduct ...What is the CARA Therapeutics stock forecast? · CARA Therapeutics stock prediction for 1 year from now: $ 7.69 (625.24%) · CARA Therapeutics stock forecast for ...Embraer S.A. 16.28. -0.04. -0.25%. In the modern age, people are ready to get excited about flying car industry stocks. Excitement continues to build around flying car stocks following recent ...Complete Cara Therapeutics Inc. stock information by Barron's. View real-time CARA stock price and news, along with industry-best analysis.

Cara Therapeutics Inc’s trailing 12-month revenue is $27.2 million with a -410.9% profit margin. Year-over-year quarterly sales growth most recently was -70.0%. Analysts expect adjusted earnings to reach $-1.998 per share for the current fiscal year. Cara Therapeutics Inc does not currently pay a dividend.Stock opname adalah aktivitas perhitungan jumlah stok barang atau produk yang menumpuk di gudang atau di toko sebelum barang tersebut. Yuk baca detailnya!10 thg 4, 2015 ... Shares of Cara began trading publicly for the first time in more than a decade on Friday and quickly jumped about 40 per cent above the ...Instagram:https://instagram. stock dddblackrock strategic income opportunitiesnasdaq nltxdechtman wealth management The average price recommended by analysts for Cara Therapeutics Inc (CARA) is $10.29, which is $9.33 above the current market price. The public float for CARA is 46.23M and currently, short sellers hold a 6.42% of that float. On November 24, 2023, CARA’s average trading volume was 599.48K shares. Top 5 EV Tech Stocks to Buy for 2023. options trading brokerfxify review Top price targets Weekly price targets Monthly price targets Yearly price targets Intraday price targets . As on 19 Mon Sep 2022 Current price of Cara Therapeutics, Inc. CARA is 9.84 and trend of stock is towards upside and stock can be bought for price targets of 10.27, 10.41, 10.52, 10.6, 10.62, 11.68, 10.82 what is odds mean What's Happening with CARA Stock Today Cara Therapeutics Inc (CARA) stock is down -4.28% while the S&P 500 has gained 1.3% as of 12:31 PM on Wednesday, Apr 27. CARA is down -$0.45 from the previous closing price of $10.51 on volume of 212,841 shares. Over the past year the S&P 500 has gained 1.02% while CARA is down -61.46%.Cara Therapeutics' CEO is Chris Posner, appointed in Nov 2021, has a tenure of 5.25 years. total yearly compensation is $2.51M, comprised of 27.9% salary and 72.1% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth $84.15K. The average tenure of the management team and the board of …